Table 1. . Anti-CD19 chimeric antigen receptor T-cell therapy in large-cell B-cell lymphoma (selected clinical trials and real-world experience).
| Trial/study | ZUMA-1 [43] | JULET [37] | TRANSCEND-NHL001 [42] | Nastoupil et al. [38] | Jacobson et al. [39] | CIBMTR [40] | CIBMTR | Sesques et al. [43] |
|---|---|---|---|---|---|---|---|---|
| CAR T product | Axi-cel | Tisa-cel | Liso-cel | Axi-cel | Axi-cel | Axi-cel | Tisa-cel | Axi-cel/Tisa-cel |
| Patients apheresed (evaluable) | 111 (101) | 165 (93) | 344 (269) | 165† | 65 | 453 (295)† | 70 (70) | 70 (61) |
| Bridging therapy (%) | 0 | 90 | 59 | 53 | 40 | NA | NA | 97% |
| Median follow-up (months) | 27.1 | 14 | 18.8 | 13.8 | 10.4 | 6.2 | 5.8 | 5.7 |
| ORR (CR) % | 83 (58) | 52 (40) | 73 (53) | 82 (64) | 70 (50) | 70 (52) | 60 (38) | 63 (48) |
| Median PFS (months) | 5.9 | 2.9 | 6.8 | 8.3 | 4.5 | NA | NA | 3.0 |
| 12-month PFS 24-month PFS |
44% 39% |
35% NA |
44% NA |
47% NA |
NA NA |
NA NA |
NA NA |
NA NA |
| 12-month OS | 60% | 49% | 57.9% | 68% | 67% | NA | NA | NA |
| CRS (any grade) CRS ≥3 |
93% 11% |
58% 22% |
42% 2% |
92% 7% |
96% 17% |
83% 14% |
NA 4.3% |
85% 8% |
| NT (any grade) NT ≥3 |
64% 32% |
21% 12% |
30% 10% |
69% 31% |
76% 38% |
61% NA |
NA 4.3% |
28% 10% |
†
Patients with adequate follow-up.
CAR T: Chimeric antigen receptor T cell; CIBMTR: Center for Blood and Marrow Transplant Research; CR: Complete response; CRS: Cytokine release syndrome; NA: Not available; NT: Neurotoxicity; ORR: Overall response rate; OS: Overall survival; PFS: Progression-free survival.